Home » Stocks » Relmada Therapeutics

Relmada Therapeutics, Inc. (RLMD)

Stock Price: $37.39 USD -1.37 (-3.53%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 568.26M
Revenue (ttm) n/a
Net Income (ttm) -22.99M
Shares Out 15.20M
EPS (ttm) -1.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $37.39
Previous Close $38.76
Change ($) -1.37
Change (%) -3.53%
Day's Open 38.54
Day's Range 35.18 - 38.54
Day's Volume 126,916
52-Week Range 35.18 - 54.00

More Stats

Market Cap 568.26M
Enterprise Value 453.34M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 15.20M
Float 7.51M
EPS (basic) -1.91
EPS (diluted) -1.97
FCF / Share -0.92
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.22M
Short Ratio 7.33
Short % of Float 14.99%
Beta 0.62
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.24
Revenue n/a
Operating Income -22.38M
Net Income -22.99M
Free Cash Flow -13.51M
Net Cash 114.92M
Net Cash / Share 7.56
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -158.57%
ROE -25.63%
ROIC -52.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$67.83*
(81.41% upside)
Low
50.0
Current: $37.39
High
75.0
Target: 67.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-12.73-6.92-7.22-16.22-17.10
Net Income-17.32-8.96-6.29-2.97-20.80
Shares Outstanding6.313.143.022.902.49
Earnings Per Share-2.74-2.86-2.08-1.04-8.36
Operating Cash Flow-10.50-6.00-6.47-13.14-16.23
Capital Expenditures--0.01-0.05-0.56-0.02
Free Cash Flow-10.50-6.01-6.52-13.71-16.25
Cash & Equivalents9.222.241.718.5022.47
Total Debt0.362.940.280.270.26
Net Cash / Debt8.85-0.701.438.2322.21
Assets10.223.052.8410.2424.39
Liabilities2.618.561.383.2015.58
Book Value7.61-5.511.467.048.81
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Relmada Therapeutics, Inc.
Country United States
Employees 6
CEO Sergio Traversa

Stock Information

Ticker Symbol RLMD
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: RLMD

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.